Tags : Kamada

Insights+ Key Biosimilars Events of December 2019

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar […]Read More

PharmaShots Weekly Snapshot (December 02-06, 2019)

1.  Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders Published: Dec 05, 2019 | Tags: Sage Therapeutics, Reports, Results, SAGE-217, P-III, MOUNTAIN Study, Major Depressive Disorders  2. UCB Reports Results of Bimekizumab in P-III BE SURE Study for Moderate-To-Severe Chronic Plaque Psoriasis Published: Dec 06, 2019 | Tags: UCB, […]Read More

Kamada Collaborates with Alvotech to Commercialize its Six Biosimilar Products

Shots: Kamada will commercialize Alvotech’s biosimilar portfolio consisting of 6 products in Israel, upon its Israeli Ministry of Health (IMOH) approval while Alvotech will remain responsible for development, manufacturing and supply of all products The collaboration leverages Kamada’s expertise and presence in the Israeli market and enables Kamada to benefit from the long-term growth potential […]Read More